Annexon (ANNX) Competitors $2.52 -0.13 (-4.91%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$2.56 +0.04 (+1.39%) As of 09/17/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANNX vs. CRMD, TSHA, IMNM, AMLX, IOVA, PHAT, URGN, TRVI, DNTH, and AVBPShould you be buying Annexon stock or one of its competitors? The main competitors of Annexon include CorMedix (CRMD), Taysha Gene Therapies (TSHA), Immunome (IMNM), Amylyx Pharmaceuticals (AMLX), Iovance Biotherapeutics (IOVA), Phathom Pharmaceuticals (PHAT), Urogen Pharma (URGN), Trevi Therapeutics (TRVI), Dianthus Therapeutics (DNTH), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry. Annexon vs. Its Competitors CorMedix Taysha Gene Therapies Immunome Amylyx Pharmaceuticals Iovance Biotherapeutics Phathom Pharmaceuticals Urogen Pharma Trevi Therapeutics Dianthus Therapeutics ArriVent BioPharma CorMedix (NASDAQ:CRMD) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability. Do analysts recommend CRMD or ANNX? CorMedix presently has a consensus target price of $18.00, suggesting a potential upside of 61.87%. Annexon has a consensus target price of $12.50, suggesting a potential upside of 396.03%. Given Annexon's higher probable upside, analysts clearly believe Annexon is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Annexon 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is CRMD or ANNX more profitable? CorMedix has a net margin of 42.11% compared to Annexon's net margin of 0.00%. CorMedix's return on equity of 42.73% beat Annexon's return on equity.Company Net Margins Return on Equity Return on Assets CorMedix42.11% 42.73% 34.19% Annexon N/A -70.04%-57.67% Do insiders & institutionals believe in CRMD or ANNX? 34.2% of CorMedix shares are held by institutional investors. 5.3% of CorMedix shares are held by insiders. Comparatively, 11.9% of Annexon shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, CRMD or ANNX? CorMedix has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$43.47M19.97-$17.93M$0.7514.83AnnexonN/AN/A-$138.20M-$1.29-1.95 Which has more volatility & risk, CRMD or ANNX? CorMedix has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, Annexon has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Does the media refer more to CRMD or ANNX? In the previous week, CorMedix had 21 more articles in the media than Annexon. MarketBeat recorded 22 mentions for CorMedix and 1 mentions for Annexon. CorMedix's average media sentiment score of 0.45 beat Annexon's score of 0.00 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 9 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annexon 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCorMedix beats Annexon on 14 of the 16 factors compared between the two stocks. Get Annexon News Delivered to You Automatically Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANNX vs. The Competition Export to ExcelMetricAnnexonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$291.20M$3.12B$5.74B$10.30BDividend YieldN/A2.37%5.86%4.62%P/E Ratio-1.9521.0377.1026.52Price / SalesN/A249.02451.8387.93Price / CashN/A45.4837.2260.63Price / Book0.929.5613.846.31Net Income-$138.20M-$53.02M$3.29B$271.37M7 Day Performance-1.18%-1.58%-0.75%0.57%1 Month Performance7.23%2.82%3.84%6.20%1 Year Performance-63.64%9.34%84.93%28.33% Annexon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANNXAnnexon2.329 of 5 stars$2.52-4.9%$12.50+396.0%-63.9%$291.20MN/A-1.9560CRMDCorMedix3.9108 of 5 stars$12.75+2.8%$17.33+35.9%+54.2%$925.65M$43.47M17.0030Insider TradeTSHATaysha Gene Therapies2.452 of 5 stars$3.24-3.6%$8.29+155.7%+33.0%$916.59M$8.33M-9.53180IMNMImmunome2.2168 of 5 stars$9.40-10.6%$22.89+143.5%-41.6%$915.71M$9.04M-3.0540Positive NewsAMLXAmylyx Pharmaceuticals2.3218 of 5 stars$10.44+2.4%$12.25+17.3%+337.3%$909.51M$87.37M-4.18200Analyst ForecastIOVAIovance Biotherapeutics4.3331 of 5 stars$2.38-4.4%$11.90+400.0%-78.7%$901.02M$164.07M-1.93500PHATPhathom Pharmaceuticals2.3936 of 5 stars$12.43+0.7%$17.50+40.8%-40.5%$875.45M$55.25M-2.63110URGNUrogen Pharma4.0906 of 5 stars$21.42+13.5%$32.00+49.4%+41.0%$873.47M$90.40M-6.45200Positive NewsHigh Trading VolumeTRVITrevi Therapeutics2.8392 of 5 stars$7.60+8.4%$20.11+164.6%+139.6%$853.66MN/A-18.0920Positive NewsHigh Trading VolumeDNTHDianthus Therapeutics2.9109 of 5 stars$31.80+20.0%$54.00+69.8%+49.6%$852.99M$6.24M-9.7880Gap UpHigh Trading VolumeAVBPArriVent BioPharma2.0182 of 5 stars$20.21+0.1%$39.14+93.7%-26.9%$819.09MN/A-5.0340Positive News Related Companies and Tools Related Companies CRMD Competitors TSHA Competitors IMNM Competitors AMLX Competitors IOVA Competitors PHAT Competitors URGN Competitors TRVI Competitors DNTH Competitors AVBP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANNX) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTen Bucks, Five Minutes... Could Send You Up to $8K QUARTERLYDOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredWhy Peter Thiel Hid Gold in a VaultSilicon Valley billionaires hiding gold in vaults? Peter Thiel’s Palantir quietly diverted tens of millions...Golden Portfolio | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANNX Stock Alerts